A novel ribosomal protein S6 kinase 2 inhibitor attenuates the malignant phenotype of cutaneous malignant melanoma cells by inducing cell cycle arrest and apoptosis. Issue 5 (2nd May 2022)

• Record Type: Journal Article
• Authors: Li, Yayun; Yu, Pian; Long, Jing; Tang, Ling; Zhang, Xu; Zhou, Zhe; Cao, DongSheng; Su, Juan; Chen, Xiang; Peng, Cong
• Is Part Of: Bioengineered. Volume 13:Issue 5(2022)
• Page Start: 13555
• Page End: 13570
• Publication Date: 2022-05-02
• Subjects: Melanoma -- RSK2 -- AE007 -- cell cycle arrest -- apoptosis; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2022.2080364
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Malignant melanoma (MM) is a highly life-threatening tumor causing the majority of the cutaneous cancer-related deaths. Previously, ribosomal protein S6 kinase 2 (RSK2), the downstream effector of the MAPK pathway, represents a therapeutic target in melanoma. AE007 is discovered as a targeted RSK2 inhibitor, and subsequent results showed that AE007 inhibits RSK2 by directly binding to its protein kinase domain. AE007 causes cell cycle arrest and cellular apoptosis, thereby dramatically inhibiting proliferation, migration, and invasion of melanoma cells. Nevertheless, melanocytes and keratinocytes are not affected by this compound. In addition, suppression of RSK2 abrogates the inhibitory effect of AE007 on melanoma cell proliferation. AE007 treatment significantly inhibits the expression of Cyclin D1, Cyclin B1, CDK2, and Bcl-2, while raises the cleavage of PARP. Moreover, RNA sequencing results show that AE007 treatment can affect the genes expression profile, including the expression of cell cycle and DNA replication genes. In conclusion, AE007 is a promising melanoma therapeutic agent by targeting RSK2. Graphical Abstract: uf0001